Key Points
- Jeju National University and Johns Hopkins Medicine have partnered to test nanoparticle-formulated curcumin on human cardiac organoids to prevent heart disease and neurodegenerative conditions.
- The breakthrough overcomes curcumin's notoriously poor natural absorption by encapsulating it into 100-nanometer spheres, which previously showed anti-inflammatory success in animal trials.
- Curcumin has ancient roots in traditional Korean medicine (hanbang) as an anti-inflammatory powerhouse, and this project bridges traditional heritage with modern medical science.
Summary Researchers in South Korea and the United States are joining forces to unlock the medical potential of curcumin, the vivid yellow compound best known as the active ingredient in turmeric and curry. Jeju National University’s Jeju International Animal Research Center announced a new five-year collaborative research initiative with the Cardiovascular Stem Cell Center (CSCC) at Johns Hopkins University School of Medicine to explore curcumin’s role in preventing cardiovascular disease, Parkinson's disease, and dementia.
Curcumin has long held a revered status in traditional Korean medicine (hanbang), prized across generations for its robust natural anti-inflammatory and antioxidant properties. However, its therapeutic applications have historically faced a significant obstacle: curcumin has remarkably low water solubility, meaning the human body struggles to absorb it effectively when ingested.
To overcome this bioavailability bottleneck, the Jeju research team leveraged cutting-edge nanotechnology to formulate "curcumin nanospheres"—wrapping the compound in polymer nanoparticles measuring approximately 100 nanometers. In preliminary trials conducted on weaned piglets, the nanospheres demonstrated remarkable promise, lowering inflammatory markers while boosting gut microbiome diversity.
Through this landmark cross-border partnership, the research will now progress to human cellular models. Johns Hopkins University will evaluate the nanospheres using induced pluripotent stem cell (iPSC)-derived cardiac organoids—three-dimensional mini-tissues that closely replicate the architectural and physiological functions of the human heart. If these human cellular trials succeed, the joint team plans to expand into pre-clinical large-animal models before ultimately targeting preventive interventions for debilitating human conditions such as heart disease, Parkinson's, and Alzheimer's dementia.
The collaboration represents a rare and synergistic convergence where South Korean agricultural science meets world-class American medical biotechnology. Formalized during the 33rd Inter-Academy Workshop on brain and heart diseases held at Johns Hopkins, the partnership also includes plans to jointly pursue basic research funding from South Korea’s Ministry of Science and ICT and conduct ongoing researcher exchanges.
Sponsored · Ad